Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
BUFFALO, N.Y. — A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Comprehensive Cancer Center (Roswell Park) has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2). Study results published in the peer-reviewed American Association for Cancer Research journal Cancer Research showed that FL118 can also activate the p53 tumor-suppressor pathway in cancer cells, encouraging cell senescence, or aging. In both processes, FL118 demonstrates potent antitumor efficacy, suggesting additional applications as a personalized, targeted therapy for certain cancer tumors.
In a study of preclinical models of colorectal cancer, the researchers identified an underlying mechanism for the activation of p53 by FL118. The agent activates the p53 tumor-suppressor protein largely independent of ataxia telangiectasia mutated (ATM)-dependent DNA damage-mediated p53 activation. ATM-dependent activation of p53 is usually induced by many — if not all — types of DNA-damage drugs, including camptothecin compounds such as irinotecan and topotecan, leading the authors to conclude that FL118’s mechanisms of action are distinct among camptothecin analogues.
“While FL118 is an analogue of irinotecan and topotecan, two FDA-approved cancer drugs that are also based on the naturally occurring compound camptothecin, our findings add further evidence that FL118 has novel mechanisms of action that may make it especially potent against solid tumors and especially effective as a well-tolerated, targeted therapy,” said Dr. Li, an Associate Professor of Oncology in the Department of Pharmacology and Therapeutics.
The study showed that FL118 inhibits p53 polyubiquitination and monoubiquitination through the oncogenic Mdm2-MdmX E3 complex, while stimulating Mdm2-mediated MdmX ubiquitination — by changing the target specificity of Mdm2-MdmX E3 complex from p53 to MdmX. This action results in accelerated degradation of MdmX, a p53-negative regulator and oncogenic protein, and activation of p53 signaling and p53-dependent senescence. Importantly, in contrast to p53-dependent senescence induction, in the absence of p53 or in the presence of MdmX overexpression, FL118 promotes p53-independent apoptosis.
“These unexpected findings open new therapeutic possibilities and support the notion that MdmX depletion is a critical mechanism for activating p53 signaling to control tumor cells,” notes Dr. Wang, an Assistant Professor of Oncology in the the Department of Pharmacology and Therapeutics. “We also found that FL118 was particularly effective against MdmX-overexpressing cells.”
The findings support investigation of FL118 as an MdmX-depleting agent in MdmX-targeting personalized cancer therapies. The authors conclude that FL118-based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.
Additional research will be needed to explore how FL118 changes the biochemical properties of the Mdm2-MdmX E3 complex. The team is also investigating the agent’s efficacy in treating pancreatic cancer and ovarian cancer.
Other key findings:
- FL118 uses different antitumor mechanisms in wild-type p53 tumors and p53-deficient tumors. In wild-type p53 tumors, FL118 induces p53/p21-dependent senescence and p53-independent apoptosis, while in p53-deficient tumors, it exclusively induces p53-indpendent apoptosis. Because it more effectively induces cancer cell apoptosis in p53-deficient tumors, FL118 is especially effective against late-stage cancers, which usually lose functional p53 and are resistant to DNA-damage drugs.
- This newly identified dual mechanism of action supports the therapeutic potential of FL118 in targeted, personalized cancer therapeutics for both early-stage (wild-type p53) and late-stage (p53-deficient) cancers.
- Given the fact that normal cells possess wild-type p53 function, FL118-induced p53 activation might explain the favorable toxicology profile of FL118: highly toxic to cancer cells but not so in healthy animal cells, and these different consequences might be mediated through p53 activation.
- Because FL118 promotes MdmX degradation through a unique mechanism involving the ubiquitin-proteasomal pathway, it can be used as an MdmX-targeting agent, as well as an inhibitor of anti-apoptotic proteins.
The study, “Novel Mechanism of Action of FL118 Induces p53-Dependent Senescence by Targeting MdmX degradation in Colorectal Cancer Cells,” has been published online ahead of print in Cancer Research and is available at cancerres.aacrjournals.org.
This work was funded in part by grants from the U.S. Department of Defense (W81XWH-12-1-0305), the National Cancer Institute, or NCI (R21CA180764), the Roswell Park Alliance Foundation and the Mesothelioma Foundation. The study also used shared resources supported by Roswell Park’s Cancer Center Support Grant from the NCI (P30CA016056).
The mission of Roswell Park Comprehensive Cancer Center is to understand, prevent and cure cancer. Founded in 1898, Roswell Park is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email AskRoswell@Roswellpark.org. Follow Roswell Park on Facebook and Twitter.
Annie Deck-Miller, Senior Media Relations Manager